A Multicenter, Double-Blind, Placebo-Controlled, Randomized Withdrawal, Parallel Group Study to Evaluate the Efficacy and Safety of mg/Day of DVS SR in Adult Outpatients With Major Depressive Disorder.

Trial Profile

A Multicenter, Double-Blind, Placebo-Controlled, Randomized Withdrawal, Parallel Group Study to Evaluate the Efficacy and Safety of mg/Day of DVS SR in Adult Outpatients With Major Depressive Disorder.

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Feb 2013

At a glance

  • Drugs Desvenlafaxine (Primary)
  • Indications Major depressive disorder
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 17 Oct 2012 Results presented at the 25th Annual Congress of the European College of Neuropsychopharmacology.
    • 16 Oct 2012 Primary endpoint 'Time-to-relapse' has been met.
    • 26 Jun 2012 Actual patient number changed from 857 to 874 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top